Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection and vaccination
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.07.09.21260266: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: All participants were enrolled after written informed consent was obtained from each participant.
IRB: Studies were approved by the Research Subjects Institutional Review Board at the University of Rutgers, Newark, New Jersey (Pro2020000655, Pro2020001263, and ClinicalTrials.gov registration numbers NCT04336332 and NCT04336215).Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication Contamination: Each ELISA plate contained positive and negative serum/plasma controls and background control wells without primary antibody, and each sample was tested in duplicate. Table 2: Resources
Antibodies Sentences Reso… SciScore for 10.1101/2021.07.09.21260266: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Consent: All participants were enrolled after written informed consent was obtained from each participant.
IRB: Studies were approved by the Research Subjects Institutional Review Board at the University of Rutgers, Newark, New Jersey (Pro2020000655, Pro2020001263, and ClinicalTrials.gov registration numbers NCT04336332 and NCT04336215).Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication Contamination: Each ELISA plate contained positive and negative serum/plasma controls and background control wells without primary antibody, and each sample was tested in duplicate. Table 2: Resources
Antibodies Sentences Resources Commercial antibody detection assays: The Roche Elecsys® Anti-SARS-CoV-2 assay utilizing the Roche Cobas e601 instrument and the Abbott Architect SARS-CoV-2 IgG assay utilizing the Abbott Architect c4000, which both use SARS-CoV-2 N protein as capture antigen, were performed by specialized personnel following the manufacturer’s instructions. SARS-CoV-2 N protein as capture antigen ,suggested: NoneExperimental Models: Cell Lines Sentences Resources Non-SARS-CoV-2 antigens: Spike Protein S1 from non-SARS-CoV-2 coronaviruses (HCoV-229E, HCoV-NL63, HCoV-HKU-1) and Spike Protein S1 and S2 extracellular domain (HCoV-OC43) were obtained from Sino Biologicals (Wayne, PA, USA) and pooled in equimolar amounts to a final concentration of 1 mg/ml. HCoV-NL63suggested: RRID:CVCL_RW88)Recombinant DNA Sentences Resources 544) was amplified and cloned at the 3’ end of a gene expressing the N-terminal fragment of the Fr-MuLV SU (gp70 protein) in the eukaryotic expression vector pcDNA3.4 (Addgene, Watertown, MA). pcDNA3.4suggested: RRID:Addgene_131198)Reference SARS-COV-2 S1 RBD Protein: The reference protein was produced from the vector pCAGGS containing the SARS-Related Coronavirus 2, pCAGGSsuggested: RRID:Addgene_18926)Software and Algorithms Sentences Resources Commercial antibody detection assays: The Roche Elecsys® Anti-SARS-CoV-2 assay utilizing the Roche Cobas e601 instrument and the Abbott Architect SARS-CoV-2 IgG assay utilizing the Abbott Architect c4000, which both use SARS-CoV-2 N protein as capture antigen, were performed by specialized personnel following the manufacturer’s instructions. Abbott Architectsuggested: (Abbott ARCHITECT i1000sr System, RRID:SCR_019328)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04336332 Active, not recruiting Randomized Comparison of Combination Azithromycin and Hydrox… NCT04336215 Recruiting Rutgers COVID-19 Cohort Study Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
